Introduction
Measurement of short term lower leg growth with the knemometer has recently been shown to be a sensitive method for assessment of systemic activity of exogeneous glucocorticosteroids in children with asthma (1). It is not known, however, whether short term knemometry is more sensitive than established measures of adrenal function, such as 24 h urine free cortisol excretion. We recently found that knemometric growth rates were suppressed in a dose-related manner in asthmatic children treated with 200, 400 and 800,~g of inhaled budesonide (2). In the present paper, we report the 24 h urine free cortisol excretion in the same children for comparison with the knemometry data, to evaluate if there is any correlation between the two measures of systemic activity, and to assess which method is the more sensitive.
Patients and Methods
The protocol was part of a clinical study of the influence of inhaled budesonide on short term lower leg growth assessed with the knemometer (2). Nine boys and six girls aged 6-13 (mean 9.5) years with mild asthma participated in the study. The children were pre-adolescent outpatients in a secondary referral centre.
The study was approved by the local Ethical Committee and informed consent was obtained from all children and their parents.
The design was a randomized double-blind, crossover trial with four periods of 18 days. In periods 1 (run-in) and 3 (wash-out), placebo was given, and in periods 2 and 4, the children took 200 or 8OOpg budesonide day -'. Treatment order was allocated by means of a computerized randomization scheme The children were instructed to collect urine during the last Saturday of the first period (run-in) and of the three budesonide treatment periods. Aliquots for determination of creatinine and cortisol were collected from the 24 -h urine samples, after weighing and thorough mixing of the whole volume. The aliquots were frozen until the end of the trial when urine free cortisol concentrations were measured by radioimmunoassay (Farmos Diagnostica, Turku, Finland) (3). The intra-and interassay coefficients of variation were 1.4% and 7.1%, respectively. The cortisol concentrations were standardized in ,ug g ~ ' creatinine (4).
ANALYSIS
The creatinine standardized cortisol data were compared by the method described for cross-over trial designs (5). Neither period nor carry-over effects were found. Page's test was used to evaluate if there was any dose-related influence of budesonide on urine cortisol excretion (6). Correlation between lower leg growth velocities and urine cortisol concentrations during the run-in period and during each dose level of budesonide was assessed by Spearman's test. The 5% level was considered as significant.
Results
Figure 1 shows individual and group mean urine free cortisol/creatinine x lo6 and the previously published knemometry data during the run-in period and at each dosage level of inhaled budesonide.
No statistically significant dose-related influence of budesonide treatment was found on urine free cortisol levels either when the open 400,~g period was excluded from analysis (P=O.13; z= -1.5) or when it was included (P=O.O6; z= -1.8). The mean reduction (SEM) during treatment with 200,400 and 800 pug budesonide was 2.2 (1.4), 2.1 (1.0) and 2.6 (1.5) cortisol/creatinine X lo6 respectively. 
Discussion
The present study seems to be the first doseresponse study in children that has included a steroid-free run-in period for comparison of the urine cortisol levels during treatment periods. No significant dose-related effects of budesonide could be detected from the urine cortisol levels. This is in agreement with the findings of another cross-over study of a larger, but otherwise comparable, population which evaluated inhaled budesonide in similar doses (7).
It is possible that nocturnal integrated plasma cortisol levels may be more sensitive in detecting effects on the hypothalamic-pituitary-adrenal feedback system than extended period measurements of urine free cortisol excretion. We wanted, however, to evaluate if we could use a simpler method than knemometry to assess systemic activity. Furthermore, results from studies using both integrated plasma levels of cortisol and urine free cortisol excretion measurements have been similar (8).
Though it is possible that a few more patients in the study group would have resulted in a statistically significant correlation between the changes in growth rates and cortisol excretion, the present data show quite clearly that measurement of 24-h urine free cortisol excretion is not as sensitive as short term knemometry in detecting systemic effects of exogeneous glucocorticosteroids in children. When new inhaled glucocorticosteroids, administration forms, regimens and inhalation devices are introduced in the management of children with asthma, knemometry should be preferred to 24-h urine free cortisol excretion for assessment of the lowest dose at which systemic activity can be detected.
